Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2942637 | 0.83 | AAK1 (0.48) | KMT2ASMN1; SMN2LMNAHPGDSMARCA2 | |
| SCHEMBL1519175 | 0.77 | KMT2A (0.46) | KMT2ASMN1; SMN2LMNAHPGDSMARCA2 | |
| SCHEMBL13284307 | 0.77 | KMT2A (0.43) | KMT2ASMN1; SMN2LMNAHPGDSMARCA2 | |
| SCHEMBL1858932 | 0.77 | PIK3CD (0.51) | KMT2ASMN1; SMN2LMNAHPGDSMARCA2 | |
| SCHEMBL17678277 | 0.75 | LMNA (0.52) | KMT2ALMNAPOLBACP1GLA | |
| SCHEMBL4039191 | 0.75 | MAPT (0.66) | KMT2ASMN1; SMN2LMNAMEN1POLB | |
| SCHEMBL9107823 | 0.75 | SMN1; SMN2 (0.57) | KMT2ASMN1; SMN2LMNAMEN1ABL1 | |
| SCHEMBL16044320 | 0.72 | MAPT (0.61) | KMT2ALMNAMEN1POLBKDM4E | |
| SCHEMBL14247587 | 0.70 | LMNA (0.52) | KMT2ALMNAPOLBACP1GLA | |
| SCHEMBL4069514 | 0.70 | SIGMAR1 (0.44) | KMT2ASMARCA2MEN1POLBACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049503-B1 | QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES AS P38 KINASE INHIBITORS | AMGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7935709-B2 | 2-quinazolinone compounds and methods of use | AMGEN INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080032973-A1 | 2-Quinazolinone compounds and methods of use | AMGEN INC. (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032973-A1 | 2-Quinazolinone compounds and methods of use | MAP3K1, MAP3K2, MAP3K7 | KMT2A 1607/4885SMN1; SMN2 4054/4885LMNA 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.